Cutler Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-5,000
Closed -$133K 6041
2021
Q3
$133K Buy
+5,000
New +$134K 0.01% 1683
2020
Q4
Sell
-500
Closed -$10K 5468
2020
Q3
$10K Hold
500
﹤0.01% 3014
2020
Q2
$11K Hold
500
﹤0.01% 2821
2020
Q1
$8K Hold
500
﹤0.01% 2855
2019
Q4
$11K Hold
500
﹤0.01% 2603
2019
Q3
$13K Hold
500
﹤0.01% 2471
2019
Q2
$16K Hold
500
﹤0.01% 2379
2019
Q1
$17K Sell
500
-2,200
-81% -$81.9K ﹤0.01% 2157
2018
Q4
$89K Buy
+2,700
New +$116K 0.01% 1104
2018
Q1
Sell
-12
Closed -$501 5175
2017
Q4
$0 Sell
12
-6,425
-100% -$254K ﹤0.01% 5882
2017
Q3
$257K Buy
6,437
+1,060
+20% +$45.9K 0.01% 1015
2017
Q2
$231K Buy
5,377
+3,177
+144% +$113K 0.01% 1168
2017
Q1
$68K Buy
+2,200
New +$59K ﹤0.01% 2092
2016
Q4
Sell
-300
Closed -$6.7K 7278
2016
Q3
$7K Sell
300
-606
-67% -$13.7K ﹤0.01% 4640
2016
Q2
$18K Sell
906
-5,500
-86% -$97.6K ﹤0.01% 3491
2016
Q1
$97K Sell
6,406
-13,778
-68% -$180K 0.01% 1652
2015
Q4
$271K Buy
+20,184
New +$312K 0.02% 946

Other funds holding SUPN

Cutler Group's SUPN Position: Q4 2021 in Review

Cutler Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2021, closing a stake of 5,000 shares — an estimated $133K sold.

Cutler Group first reported a position in SUPN in Q4 2015 and held it in 17 quarters. The position peaked at $271K in Q4 2015. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2021.

  • Cutler Group reported no remaining Supernus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 5,000 Supernus Pharmaceuticals shares in Q4 2021, an estimated $133K.
  • Cutler Group first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 17 quarters.
  • Cutler Group's Supernus Pharmaceuticals position peaked at $271K in Q4 2015.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.